Aura Biosciences, Inc. (AURA) earnings date
Mar 24, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 20 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | before open | 40 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | before open | 42 | 8-K |
| Q1 FY2026 | Mon, May 11, 2026 | after close | 41 | 8-K |
| Q4 FY2025 | Mon, Mar 30, 2026 | before open | 89 | 8-K |
| Q3 FY2025 | Thu, Nov 13, 2025 | before open | 44 | 8-K |
| Q2 FY2025 | Wed, Aug 13, 2025 | before open | 44 | 8-K |
| Q1 FY2025 | Thu, May 15, 2025 | before open | 45 | 8-K |
| Q4 FY2024 | Mon, Mar 24, 2025 | after close | 83 | 8-K |
What they guided beta
| Q3 FY2026 | "Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights Phase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits Established relationship with industry-leading CDMO providing designated manufacturing capacity for bel-sar Early choroidal melanoma investor and analyst virtual event planned for December 8, 2026 Expected cash runway into 1H 2029 BOSTON, MA – November 9, 2026 – Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”) a clinical-stage biotechnology company developing a potentially tr" exhibit |
| Q3 FY2026 | "The trial is on track to deliver topline data from the 15-month primary endpoint in the second half of 2027." exhibit |
| Q3 FY2026 | "In the first quarter of 2027, Aura expects to provide an update on both programs, including details on disease burden, trial design, and timelines to future data read-outs from these studies." exhibit |
| Q3 FY2026 | "9 th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026. o Fireside chat at 2:10 p.m. ET The live webcast of the events will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations , where a replay of the webcasts will be archived for 90 days following the presentation date." exhibit |
| Q2 FY2026 | "Organizational restructuring and disciplined capital allocation strategy to align with ocular oncology focus extend expected cash runway into 1H 2029 Strengthening leadership team with appointments of experienced industry executives as Chief Operating Officer, Chief Regulatory and Quality Officer, and Chief People Officer to position Aura for next stage of growth BOSTON, MA – August 11, 2026 – Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today reported financial r" exhibit |
| Q2 FY2026 | "Topline data from the 15-month primary endpoint remain on track for the second half of 2027, consistent with previously communicated guidance." exhibit |
| Q2 FY2026 | "Aura expects to provide an update on both programs, including guidance on study completion, in Q1 2027." exhibit |
| Q2 FY2026 | "Together with disciplined capital allocation, these actions are expected to extend the Company's projected cash runway into the first half of 2029 to support execution of the Phase 3 CoMpass trial, advancement of its additional ocular oncology programs and preparation for potential commercialization." exhibit |
| Q2 FY2026 | "The restructuring plan is expected to be substantially complete by the end of the third quarter of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/AURA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/AURA
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/AURA/"><img src="https://veritasdata.dev/embed/AURA.svg" alt="AURA earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/AURA/)
Script
<script async src="https://veritasdata.dev/embed/AURA.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/AURA"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.